Back to search

Article

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy

2024-01-10

Abstract excerpt

<h4>Background</h4> High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic malignancy despite new therapeutic concepts, including poly-ADP-ribose polymerase inhibitors (PARPis) and antiangiogenic therapy. The efficacy of immunotherapies is modest, but clinical trials investigating the potential of combination immunotherapy with PARPis are underway. Homologous recombination repair deficiency (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
92f96c5c-a753-5518-b8d0-14f4074617dd
DOI
10.1101/2024.01.09.24301038
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapyDOI 10.1101/2024.01.09.24301038
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.Semantic proximity
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.Semantic proximity
High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.Semantic proximity
Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity
Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaSemantic proximity
Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategiesSemantic proximity
Biology-driven therapy advances in high-grade serous ovarian cancerSemantic proximity
The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity
Concurrent RB1 loss and<i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaSemantic proximity
Identification of three subtypes of ovarian cancer and construction of prognostic models based on immune-related genes.Semantic proximity
Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profilingSemantic proximity
Select a neighboring publication to make it the new centre.